Enhertu accepted for use across NHS Scotland
Decision will create opportunity for therapy to be used earlier in the treatment pathway
Read More
Tag: Enhertu
AstraZeneca and Daiichi Sankyo’s Enhertu receives EU approval
Specifically engineered antibody treats HER2-positive metastatic breast cancer
Read More
Daiichi Sankyo and AstraZeneca’s Enhertu delivers promising trial results
Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer
Read More
Enhertu reduces breast cancer disease progression or death by 72%
‘Groundbreaking results’ for the treatment of HER2-positive metastatic breast cancer
Read More
Enhertu improves progression-free survival in breast cancer trial
Trial compared Enhertu with T-DM1 in patients with HER2-positive breast cancer
Read More
Enhertu accepted via cancer drugs fund for HER2-positive breast cancer
Decision is based on results from the Phase II DESTINY-Breast01 trial
Read More
AZ, Daiichi Sankyo’s Enhertu scores approval in the UK
Antibody drug conjugate conditionally approved for HER2-positive metastatic breast cancer
Read More
AZ, Daiichi Sankyo’s Enhertu wins US approval for HER2-positive gastric cancer
Approval is based on results from the Phase III DESTINY-Gastric01 trial
Read More
Enhertu scores ‘impressive’ new data in HER2+ breast cancer
Updated data from DESTINY-Breast01 trial continues to demonstrate efficacy
Read More
Enhertu bags US priority review for HER2+ gastric cancer
FDA action date for regulatory decision set during first quarter of 2021
Read More
AZ/Daiichi Sankyo’s Enhertu picks up third breakthrough designation
The drug is being developed for metastatic non-small cell lung cancer (NSCLC) in patients whose tumours have an HER2 mutation and with disease progression on or after platinum-based therapy
Read More
US nod for Lynparza in HRD-positive advanced ovarian cancer
Lynparza has been cleared for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
